市场调查报告书
商品编码
1371993
2030 年电外科市场预测:按产品类型、用途、最终用户和地区分類的全球分析Electrosurgery Market Forecasts to 2030 - Global Analysis By Product Type, Application, End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球电外科市场规模为 68 亿美元,预计预测期内年复合成长率为 10.3%,到 2030 年将达到 135 亿美元。
电外科手术是一种在外科手术过程中使用电能来切割、凝固和蒸发组织的医疗技术。特殊工具,如电极或烧灼器械,用于将受控的高频电流传递到目标组织。此外,这种能量会产生热量,根据其模式,它可以像手术刀一样切割组织或凝固并封闭血管。电外科手术提供精确性和控制,最大限度地减少出血并加快手术过程。因此,它经常用于各个医疗科室的止血、肿瘤切除和组织形成,包括一般外科、皮肤科、妇科和泌尿系统。
根据《全国医疗保健支出项目(2015-2025)》,2015年至2025年美国医疗保健费用预计平均成长5.8%。此外,该国配备人员的医院床位数量已增至 931,203 张。
微创和非侵入性手术方法比传统手术越来越受到青睐。微创手术比开放性手术有许多优点,包括恢復更快、术后併发症更少、疼痛更少。此外,这些方法比传统手术便宜。此外,雷射和电外科技术比传统手术方法变得越来越普及。发电机和主动电极等电外科工具使这些手术变得更容易、更快捷,从而增加了对其服务的需求。
对组织使用不当的电能进行切割或凝固可能会导致附近组织烧烫伤。此外,电弧可能会无意中损坏物体,并且产生的热量会产生含有传染性颗粒的烟雾。此外,患者的潜在医疗问题,例如心律调节器或金属植入物,也可能受到影响。此外,其他风险包括培训不足和设备故障。因此,这些因素预计将限制电外科市场的扩张。
政府专注于加强个人医疗保健系统中的医疗基础设施,特别是重症监护基础设施,预计将推动包括电外科行业在内的相关市场的成长。此外,许多成熟国家的政府正在采取措施,透过增加基础设施改善支出和降低医疗保健成本来改善其当前的医疗保健系统。因此,它极大地促进了市场的成长。
手术烟雾已被证明含有有害气体、蒸气、颗粒、活细胞和非活细胞材料、病毒和细菌。此外,每年约有 50 万名医疗保健专业人员吸入手术烟雾,其中包括医生、护士和外科技术人员。此外,气喘和气喘样症状是接触手术烟雾对健康的直接影响,此外还有眼睛、鼻子和喉咙发炎、头痛、咳嗽和鼻塞,因此最终将阻碍市场成长。
由于全球医疗保健系统的中断,COVID-19 大流行对电外科市场产生了负面影响。择期手术已被推迟或取消,以优先考虑 COVID-19 患者并降低感染风险。此外,医院面临财务限制,包括电外科设备在内的资本设备预算被削减。供应链中断和工厂关闭也影响了这些设备的生产和可用性。此外,患者不愿寻求非紧急护理进一步减少了对电外科的需求。此外,虽然长期电外科需求仍然强劲,但短期市场受到疫情期间手术量减少和经济限制等挑战的阻碍。
电外科发生器部分透过专门的手机和电极产生高频电流,估计占据最大份额。此外,它还具有功率设定、波形选项和安全系统等功能,这些功能对于调整组织接合的深度和精确度至关重要。这些发生器被外科医生用于各种治疗,从简单的手术到复杂的手术。此外,技术进步已经开发出更有效率、更安全的电外科发生器,提高了电外科在医疗领域的整体有效性,并逐步推动市场扩张。
预计皮肤科领域在预测期内的年复合成长率最高。皮肤科医师经常使用电外科手术去除各种皮肤病变,包括痣、疣和皮肤恶性。此外,放射线手术机等专用设备产生的高频电流可实现精确切割和凝固,从而减少疤痕并加速康復。此外,对于换肤、疤痕矫正等视觉手术,皮肤科医生也开始采用电外科手术,让患者能够治疗多种皮肤科问题,同时提供有效的治疗,减少术后併发症,凸显了电外科设备通过提供更好的美学效果的价值。 。因此,这些方面都有助于市场规模的扩大。
北美是一个由慢性病患病上升、微创手术需求增加、电外科器械技术进步、医院、诊所和门诊手术中心数量不断增加以及门诊手术偏好不断变化所驱动的市场,它获得了最大的市场由于其显着扩张,在预测期内市场占有率。
欧洲预计将在预测期内出现有益成长,因为欧洲因其强大的医疗保健系统而成为电外科仪器和技术的重要市场。其他好处包括该地区人口高龄化和慢性病患病上升,增加了手术的需求。此外,欧洲对病人安全和优质医疗保健的重视鼓励了尖端电外科技术的使用。然而,由于严格的法规标准,这些设备是安全有效的。此外,市场受益于持续的研究和创新,这推动欧洲在市场中占据关键地位。
According to Stratistics MRC, the Global Electrosurgery Market is accounted for $6.8 billion in 2023 and is expected to reach $13.5 billion by 2030 growing at a CAGR of 10.3% during the forecast period. Electrosurgery is a medical technique that employs electrical energy to cut, coagulate, or vaporize tissue during surgical procedures. It involves applying controlled, high-frequency electrical currents to the target tissue using specialized tools like electrodes or cautery equipment. Moreover, heat is created by this energy, and depending on its mode, it can either cut through tissue like a scalpel or coagulate and seal blood vessels. Electrosurgery provides accuracy and control, minimizing hemorrhage and speeding up surgical processes. Therefore, it is frequently used to produce hemostasis, remove growths, and shape tissues in a variety of medical specialties, including general surgery, dermatology, gynaecology, and urology.
According to the National Health Expenditure Projections (2015-2025), health expenditure in the US is expected to grow at an average rate of 5.8% from 2015 to 2025. The total number of staffed hospital beds in the country has also increased to 931,203.
The preference for minimally invasive and non-invasive surgical methods over conventional surgical procedures developed over time. Over open surgical methods, minimally invasive surgeries provide a number of advantages, including quicker recovery times, lower post-operative problems, and less pain. Moreover, these methods are less expensive than conventional surgical procedures. Additionally, laser and electrosurgical technologies are becoming more and more popular over traditional surgical methods. Hence, the simplicity and speed with which such surgeries can be performed are made possible by electrosurgery tools like generators and active electrodes, which boost demand for services.
If electrical energy is applied to tissue for cutting or coagulation improperly, it might result in consequences, including burns to tissue nearby. Moreover, electric arcs may unintentionally damage objects, and the heat they generate can cause smoke to be produced that could contain infectious particles. In addition, the patient's underlying medical issues, such as pacemakers or metal implants, can suffer consequences. Furthermore, other risks include inadequate training or broken equipment. Thus, these elements are expected to restrict the market for electrosurgery's expansion.
Government entities' primary focus on enhancing healthcare infrastructure, especially critical care infrastructure, in their individual healthcare systems is anticipated to boost the growth of associated markets, including the electrosurgery industry. Additionally, many sophisticated nations' governments are taking steps to improve their current healthcare systems by raising expenditures on infrastructure improvements and lowering the cost of healthcare. Therefore, significantly drive the market growth.
Surgical smoke has been demonstrated to contain hazardous gases, vapours, particles, viable and non-viable cellular material, viruses, and germs, in addition to being an annoyance due to its offensive odour and ability to obscure the surgeon's view of the surgical site. Additionally, each year, surgical smoke is inhaled by about 500,000 healthcare professionals, including doctors, nurses, and surgical technologists. Furthermore, asthma and symptoms resembling asthma are among the immediate health effects of exposure to surgical smoke, along with eye, nose, and throat irritation, headaches, coughing, and nasal congestion, therefore which eventually hinder market growth.
The COVID-19 pandemic has had a negative impact on the Electrosurgery Market due to disruptions in healthcare systems worldwide. Elective surgeries were postponed or cancelled to prioritize COVID-19 patients and reduce the risk of transmission. Moreover, hospitals faced financial constraints, leading to reduced budgets for capital equipment, including electrosurgical devices. Supply chain disruptions and factory closures also affected the production and availability of these devices. Additionally, patients' reluctance to seek non-urgent medical care further decreased the demand for electrosurgical procedures. Furthermore, while the long-term demand for electrosurgery remains strong, the short-term market faced challenges in terms of reduced procedure volumes and economic constraints during the pandemic which thus hampered the market.
The electrosurgery generators segment is estimated to hold the largest share, due to specialized handpieces and electrodes, these generators produce high-frequency electrical currents. Additionally, they have features including power settings, waveform options, and safety systems, and they are crucial in regulating the depth and accuracy of tissue engagement. These generators are used by surgeons for a variety of treatments, from straightforward operations to complicated ones. Furthermore, Advancements in technology have led to more efficient and safer electrosurgical generators, enhancing the overall effectiveness of electrosurgery in the medical field which gradually propel the market's expansion.
The dermatology segment is anticipated to have highest CAGR during the forecast period. Dermatologists frequently employ electrosurgery to remove various skin lesions, including moles, warts, and skin malignancies. Moreover, the precise cutting and coagulation made possible by high-frequency electrical currents generated by specialist equipment, such as radiosurgery units, reduces scarring and speeds up recovery. Furthermore, for visual operations like skin resurfacing and scar modification, dermatologists also employ electrosurgery, and while addressing a wide range of dermatological problems, this section highlights the value of electrosurgical equipment by providing patients with efficient treatments with fewer postoperative complications and better aesthetic results. Hence, these aspects help in boosting the market size.
North America commanded the largest market share during the extrapolated period owing to the rising prevalence of chronic diseases, rising demand for minimally invasive procedures, technological advancements in electrosurgical instruments, rising number of hospitals, clinics, and ambulatory surgical centers, and shifting preference toward outpatient surgeries which significantly driven the market expansion.
Europe is expected to witness profitable growth over the projection period, owing to the robust healthcare system in Europe makes it an important market for electrosurgical tools and techniques. Additionally, the industry has benefited from the region's aging population and rising prevalence of chronic diseases, driving the need for surgical procedures. Furthermore, Europe prioritizes patient safety and high-quality healthcare, which promotes the use of cutting-edge electrosurgical technology. However, these devices are safe and effective because of the strict regulatory criteria. Additionally, the market gains from ongoing research and innovation, which propels Europe to a significant position in the market.
Some of the key players in the Electrosurgery Market include: AngioDynamics Inc., B. Braun Melsungen AG, Johnson & Johnson Private Limited, Stryker Corporation, Heal Force Bio-meditech Holdings Limited, Smith & Nephew, Bovie Medical Corporation, Boston Scientific Corporation, Medtronic Plc. and Erbe Elektromedizin GmbH.
In September 2023, Boston Scientific Corporation announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
In September 2023, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain.
In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.